Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.
Also called NCT01630278
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 363 participants
- Sponsor
- Registry
-
NCT01630278
-
- Other papers using this trial's data
- Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT01630278. Randomized; quadruple masking; primary purpose treatment. Start 2012-03 (actual); primary completion 2019-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)
- Acronym
- TRIOCAPI
- Condition
- Patent Ductus Arteriosus
- Intervention (Drug)
- Ibuprofen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Nantes University Hospital
Record details
- Record id
cardio:ct-nct01630278- Content hash
e608d4bb4824a20d90bc3883b3f274c321a0c6a0e2cd88022bf487fe0385a274